 Christopher Ford
Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 19 | 2023 | 236 | 5.080 |
Why?
| | Receptors, Dopamine D2 | 12 | 2022 | 86 | 3.860 |
Why?
| | Corpus Striatum | 10 | 2022 | 126 | 3.400 |
Why?
| | Cholinergic Neurons | 4 | 2019 | 15 | 2.370 |
Why?
| | Synaptic Transmission | 12 | 2023 | 227 | 2.250 |
Why?
| | Inhibitory Postsynaptic Potentials | 9 | 2016 | 28 | 2.190 |
Why?
| | Nucleus Accumbens | 6 | 2021 | 124 | 2.030 |
Why?
| | Neurons | 17 | 2021 | 1279 | 1.930 |
Why?
| | Substantia Nigra | 7 | 2023 | 38 | 1.540 |
Why?
| | Dopaminergic Neurons | 7 | 2023 | 43 | 1.490 |
Why?
| | Synapses | 6 | 2021 | 330 | 1.480 |
Why?
| | Ventral Tegmental Area | 8 | 2023 | 45 | 1.360 |
Why?
| | Interneurons | 6 | 2021 | 96 | 1.290 |
Why?
| | Locus Coeruleus | 3 | 2022 | 19 | 1.110 |
Why?
| | Glutamic Acid | 4 | 2022 | 211 | 1.050 |
Why?
| | Ganglia, Sympathetic | 4 | 2008 | 18 | 0.980 |
Why?
| | Dynorphins | 2 | 2022 | 9 | 0.900 |
Why?
| | Receptors, Dopamine D1 | 2 | 2021 | 25 | 0.880 |
Why?
| | Parkinsonian Disorders | 2 | 2021 | 28 | 0.870 |
Why?
| | Neostriatum | 2 | 2021 | 29 | 0.840 |
Why?
| | Cholinergic Agents | 2 | 2019 | 15 | 0.830 |
Why?
| | Thalamus | 2 | 2021 | 74 | 0.810 |
Why?
| | Neural Inhibition | 5 | 2009 | 140 | 0.780 |
Why?
| | Neurotransmitter Agents | 5 | 2023 | 75 | 0.780 |
Why?
| | Mice | 26 | 2022 | 14860 | 0.750 |
Why?
| | Animals | 36 | 2023 | 31694 | 0.730 |
Why?
| | Parasympathetic Nervous System | 1 | 2021 | 24 | 0.730 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.730 |
Why?
| | Cocaine-Related Disorders | 1 | 2021 | 107 | 0.700 |
Why?
| | Action Potentials | 5 | 2019 | 406 | 0.700 |
Why?
| | Cocaine | 2 | 2021 | 153 | 0.680 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2019 | 180 | 0.660 |
Why?
| | Norepinephrine | 3 | 2022 | 201 | 0.660 |
Why?
| | Mesencephalon | 5 | 2023 | 57 | 0.650 |
Why?
| | Calcium Channels | 4 | 2019 | 145 | 0.650 |
Why?
| | Parkinson Disease | 1 | 2023 | 345 | 0.650 |
Why?
| | Patch-Clamp Techniques | 11 | 2012 | 239 | 0.610 |
Why?
| | Acetylcholine | 4 | 2021 | 166 | 0.610 |
Why?
| | Mice, Inbred C57BL | 12 | 2021 | 4689 | 0.600 |
Why?
| | Dendrites | 3 | 2019 | 85 | 0.550 |
Why?
| | Receptors, Opioid | 1 | 2016 | 19 | 0.550 |
Why?
| | Receptor, Muscarinic M4 | 1 | 2016 | 2 | 0.540 |
Why?
| | Cerebral Cortex | 1 | 2019 | 380 | 0.530 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 39 | 0.510 |
Why?
| | Serotonergic Neurons | 1 | 2015 | 24 | 0.510 |
Why?
| | Nerve Growth Factors | 2 | 2008 | 71 | 0.510 |
Why?
| | Raphe Nuclei | 1 | 2015 | 110 | 0.490 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2008 | 188 | 0.480 |
Why?
| | Receptors, Nicotinic | 1 | 2016 | 274 | 0.460 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2014 | 14 | 0.460 |
Why?
| | Potassium Channels | 3 | 2010 | 121 | 0.460 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 2 | 2004 | 24 | 0.450 |
Why?
| | Optogenetics | 4 | 2019 | 95 | 0.450 |
Why?
| | Axons | 3 | 2023 | 177 | 0.440 |
Why?
| | Electric Stimulation | 6 | 2012 | 250 | 0.410 |
Why?
| | Corticotropin-Releasing Hormone | 3 | 2022 | 67 | 0.400 |
Why?
| | Synaptic Vesicles | 2 | 2023 | 38 | 0.380 |
Why?
| | In Vitro Techniques | 7 | 2012 | 1016 | 0.350 |
Why?
| | Signal Transduction | 6 | 2018 | 4509 | 0.350 |
Why?
| | Neuronal Plasticity | 3 | 2021 | 209 | 0.340 |
Why?
| | Time Factors | 8 | 2014 | 6112 | 0.340 |
Why?
| | Mice, Inbred DBA | 5 | 2015 | 173 | 0.330 |
Why?
| | Egtazic Acid | 2 | 2009 | 44 | 0.330 |
Why?
| | Receptors, AMPA | 2 | 2021 | 119 | 0.320 |
Why?
| | Mice, Transgenic | 3 | 2021 | 1947 | 0.320 |
Why?
| | Sodium Channels | 2 | 2010 | 62 | 0.320 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 3 | 2016 | 4 | 0.310 |
Why?
| | Organ Culture Techniques | 3 | 2014 | 140 | 0.300 |
Why?
| | Male | 21 | 2022 | 55554 | 0.290 |
Why?
| | Electrochemistry | 4 | 2012 | 79 | 0.290 |
Why?
| | Adrenergic Neurons | 2 | 2018 | 4 | 0.280 |
Why?
| | Receptors, Opioid, kappa | 1 | 2006 | 11 | 0.280 |
Why?
| | Rana catesbeiana | 5 | 2008 | 12 | 0.260 |
Why?
| | Limbic System | 1 | 2006 | 43 | 0.260 |
Why?
| | Narcotics | 1 | 2006 | 44 | 0.260 |
Why?
| | Prefrontal Cortex | 1 | 2008 | 262 | 0.250 |
Why?
| | Serotonin | 3 | 2015 | 292 | 0.240 |
Why?
| | Female | 17 | 2022 | 59466 | 0.240 |
Why?
| | GABA Antagonists | 3 | 2010 | 32 | 0.240 |
Why?
| | Neural Pathways | 3 | 2012 | 261 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 1842 | 0.230 |
Why?
| | Calcium | 5 | 2012 | 1104 | 0.210 |
Why?
| | Membrane Potentials | 4 | 2011 | 248 | 0.210 |
Why?
| | Movement Disorders | 1 | 2022 | 48 | 0.200 |
Why?
| | Basal Ganglia | 1 | 2022 | 44 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 128 | 0.200 |
Why?
| | Heroin | 1 | 2021 | 23 | 0.190 |
Why?
| | Biophysics | 3 | 2011 | 69 | 0.190 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2022 | 144 | 0.190 |
Why?
| | Rats, Sprague-Dawley | 3 | 2019 | 2218 | 0.180 |
Why?
| | Extinction, Psychological | 1 | 2021 | 78 | 0.180 |
Why?
| | Behavior, Animal | 2 | 2021 | 458 | 0.180 |
Why?
| | Phosphinic Acids | 2 | 2010 | 9 | 0.170 |
Why?
| | Analysis of Variance | 3 | 2012 | 1226 | 0.170 |
Why?
| | Rats | 4 | 2021 | 4958 | 0.170 |
Why?
| | Adaptor Protein Complex 3 | 1 | 2019 | 2 | 0.170 |
Why?
| | Propanolamines | 2 | 2010 | 90 | 0.160 |
Why?
| | HEK293 Cells | 2 | 2019 | 591 | 0.160 |
Why?
| | Enzyme Inhibitors | 4 | 2008 | 750 | 0.160 |
Why?
| | Exocytosis | 1 | 2019 | 89 | 0.160 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2018 | 34 | 0.160 |
Why?
| | Single-Domain Antibodies | 1 | 2018 | 2 | 0.150 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2018 | 7 | 0.150 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2018 | 12 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2018 | 12 | 0.150 |
Why?
| | Botulinum Toxins | 1 | 2019 | 39 | 0.150 |
Why?
| | Oxidopamine | 1 | 2017 | 12 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 771 | 0.140 |
Why?
| | Chelating Agents | 2 | 2009 | 65 | 0.140 |
Why?
| | Subthalamic Nucleus | 1 | 2017 | 39 | 0.140 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2016 | 4 | 0.140 |
Why?
| | Ambenonium Chloride | 1 | 2016 | 1 | 0.140 |
Why?
| | Cholinesterase Inhibitors | 1 | 2016 | 24 | 0.130 |
Why?
| | Neurotensin | 1 | 2015 | 11 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2019 | 3881 | 0.120 |
Why?
| | Stress, Psychological | 2 | 2015 | 944 | 0.120 |
Why?
| | Drug Interactions | 2 | 2006 | 338 | 0.110 |
Why?
| | Mice, Knockout | 2 | 2018 | 2565 | 0.110 |
Why?
| | Ion Channel Gating | 2 | 2004 | 83 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2018 | 640 | 0.110 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2011 | 87 | 0.110 |
Why?
| | Guinea Pigs | 1 | 2012 | 136 | 0.100 |
Why?
| | Methyl-CpG-Binding Protein 2 | 1 | 2011 | 11 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2015 | 665 | 0.090 |
Why?
| | Species Specificity | 1 | 2012 | 542 | 0.090 |
Why?
| | Calcium Channels, T-Type | 1 | 2010 | 16 | 0.090 |
Why?
| | Adenosine Triphosphate | 2 | 2003 | 430 | 0.090 |
Why?
| | Iontophoresis | 1 | 2010 | 13 | 0.090 |
Why?
| | Picrotoxin | 1 | 2009 | 12 | 0.090 |
Why?
| | Quinpirole | 1 | 2009 | 9 | 0.090 |
Why?
| | Dextrans | 1 | 2010 | 73 | 0.080 |
Why?
| | Rhodamines | 1 | 2009 | 17 | 0.080 |
Why?
| | Dizocilpine Maleate | 1 | 2009 | 14 | 0.080 |
Why?
| | Dopamine Agonists | 1 | 2009 | 32 | 0.080 |
Why?
| | Quinoxalines | 1 | 2009 | 60 | 0.080 |
Why?
| | Anxiety | 1 | 2015 | 840 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 385 | 0.080 |
Why?
| | Phorbol Esters | 1 | 2008 | 15 | 0.080 |
Why?
| | rap1 GTP-Binding Proteins | 1 | 2008 | 4 | 0.080 |
Why?
| | Humans | 8 | 2022 | 114623 | 0.070 |
Why?
| | Indoles | 1 | 2010 | 304 | 0.070 |
Why?
| | Receptors, Presynaptic | 1 | 2007 | 5 | 0.070 |
Why?
| | Electric Conductivity | 2 | 2004 | 88 | 0.070 |
Why?
| | Sulpiride | 2 | 2022 | 5 | 0.070 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2007 | 98 | 0.070 |
Why?
| | Temperature | 1 | 2009 | 565 | 0.070 |
Why?
| | Synaptic Membranes | 1 | 2006 | 18 | 0.070 |
Why?
| | Organic Chemicals | 1 | 2008 | 112 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 278 | 0.070 |
Why?
| | Bicuculline | 1 | 2006 | 21 | 0.070 |
Why?
| | Biotin | 1 | 2006 | 20 | 0.070 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 27 | 0.070 |
Why?
| | Microinjections | 1 | 2006 | 76 | 0.070 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2006 | 68 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1629 | 0.070 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2006 | 127 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 303 | 0.060 |
Why?
| | Naloxone | 1 | 2006 | 97 | 0.060 |
Why?
| | Dialysis | 1 | 2004 | 17 | 0.060 |
Why?
| | Amygdala | 1 | 2006 | 170 | 0.060 |
Why?
| | Intracellular Space | 1 | 2004 | 68 | 0.060 |
Why?
| | Analgesics | 1 | 2006 | 158 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2006 | 136 | 0.060 |
Why?
| | Reaction Time | 1 | 2006 | 376 | 0.060 |
Why?
| | Vesicular Monoamine Transport Proteins | 1 | 2023 | 5 | 0.060 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2003 | 9 | 0.060 |
Why?
| | Calcium Channels, N-Type | 1 | 2003 | 5 | 0.060 |
Why?
| | Denervation | 1 | 2003 | 18 | 0.060 |
Why?
| | Recurrence | 2 | 2021 | 935 | 0.060 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2003 | 1 | 0.060 |
Why?
| | 1-Phosphatidylinositol 4-Kinase | 1 | 2003 | 3 | 0.060 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2003 | 4 | 0.060 |
Why?
| | Receptors, LHRH | 1 | 2003 | 14 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2003 | 9 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2003 | 41 | 0.050 |
Why?
| | Heparin | 1 | 2004 | 224 | 0.050 |
Why?
| | Aluminum | 1 | 2003 | 34 | 0.050 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2003 | 48 | 0.050 |
Why?
| | COS Cells | 1 | 2003 | 175 | 0.050 |
Why?
| | Androstadienes | 1 | 2003 | 97 | 0.050 |
Why?
| | Hyperkinesis | 1 | 2022 | 13 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2003 | 107 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 65 | 0.050 |
Why?
| | Sympathetic Nervous System | 1 | 2002 | 171 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2785 | 0.050 |
Why?
| | Antibodies | 1 | 2003 | 371 | 0.050 |
Why?
| | Self Administration | 1 | 2021 | 122 | 0.050 |
Why?
| | Gait | 1 | 2022 | 249 | 0.040 |
Why?
| | Dopamine Antagonists | 2 | 2011 | 22 | 0.040 |
Why?
| | Protein Binding | 2 | 2018 | 1889 | 0.040 |
Why?
| | Vesicle-Associated Membrane Protein 2 | 1 | 2019 | 15 | 0.040 |
Why?
| | Cryptochromes | 1 | 2019 | 23 | 0.040 |
Why?
| | SNARE Proteins | 1 | 2019 | 37 | 0.040 |
Why?
| | Electrophysiology | 2 | 2010 | 201 | 0.040 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2018 | 2 | 0.040 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 5 | 0.040 |
Why?
| | Gene Expression | 1 | 2003 | 1421 | 0.040 |
Why?
| | Arabidopsis Proteins | 1 | 2019 | 65 | 0.040 |
Why?
| | Guanosine Triphosphate | 1 | 2018 | 85 | 0.040 |
Why?
| | Dimerization | 1 | 2018 | 176 | 0.040 |
Why?
| | Ribosomes | 1 | 2018 | 148 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 225 | 0.030 |
Why?
| | Light | 1 | 2019 | 336 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2018 | 385 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2319 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2019 | 268 | 0.030 |
Why?
| | Receptors, Neurotensin | 1 | 2015 | 12 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1230 | 0.030 |
Why?
| | Protein Kinase C | 2 | 2010 | 273 | 0.030 |
Why?
| | Presynaptic Terminals | 1 | 2015 | 55 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1168 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 821 | 0.030 |
Why?
| | Calcineurin | 1 | 2015 | 89 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 3344 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1313 | 0.030 |
Why?
| | Tritium | 1 | 2011 | 66 | 0.020 |
Why?
| | Radioligand Assay | 1 | 2011 | 43 | 0.020 |
Why?
| | Neural Conduction | 1 | 2011 | 78 | 0.020 |
Why?
| | Electrochemical Techniques | 1 | 2011 | 45 | 0.020 |
Why?
| | Cochlear Nucleus | 1 | 2010 | 5 | 0.020 |
Why?
| | Receptors, Dopamine D3 | 1 | 2010 | 4 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2010 | 12 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2010 | 49 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2762 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2552 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 169 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2010 | 109 | 0.020 |
Why?
| | Receptors, GABA-B | 1 | 2009 | 7 | 0.020 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 32 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2009 | 67 | 0.020 |
Why?
| | Colforsin | 1 | 2007 | 48 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 139 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 54 | 0.020 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2009 | 159 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1715 | 0.020 |
Why?
| | Age Factors | 1 | 2011 | 2894 | 0.010 |
Why?
| | Phenanthridines | 1 | 2002 | 6 | 0.010 |
Why?
| | Benzophenanthridines | 1 | 2002 | 10 | 0.010 |
Why?
| | Thapsigargin | 1 | 2002 | 18 | 0.010 |
Why?
| | Estrenes | 1 | 2002 | 15 | 0.010 |
Why?
| | Alkaloids | 1 | 2002 | 22 | 0.010 |
Why?
| | Culture Techniques | 1 | 2002 | 78 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 27 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 26 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2002 | 25 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2002 | 73 | 0.010 |
Why?
| | ras Proteins | 1 | 2002 | 138 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2009 | 947 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 192 | 0.010 |
Why?
|
|
Ford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|